Quark Pharmaceuticals Development Partner Pfizer Presents In Vivo Activity of PF-04523655 at ARVO
FREMONT, Calif., May 6, 2010 - Quark Pharmaceuticals, Inc., the world leader in clinical development of RNAi-based therapeutics, announced today that researchers from Pfizer, Inc. presented data on in vivo activity of PF-04523655 at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, being held May 2-6, 2010 in Fort Lauderdale. PF-04523655 is